JP2016526920A - 最適化a−バルジを有する組換えベクター - Google Patents
最適化a−バルジを有する組換えベクター Download PDFInfo
- Publication number
- JP2016526920A JP2016526920A JP2016533383A JP2016533383A JP2016526920A JP 2016526920 A JP2016526920 A JP 2016526920A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016526920 A JP2016526920 A JP 2016526920A
- Authority
- JP
- Japan
- Prior art keywords
- replication competent
- retrovirus
- sequence
- recombinant replication
- competent retrovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361862433P | 2013-08-05 | 2013-08-05 | |
US61/862,433 | 2013-08-05 | ||
PCT/US2014/049831 WO2015021077A1 (en) | 2013-08-05 | 2014-08-05 | Recombinant vector with optimized a-bulge |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016526920A true JP2016526920A (ja) | 2016-09-08 |
JP2016526920A5 JP2016526920A5 (enrdf_load_stackoverflow) | 2017-09-14 |
Family
ID=52461883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533383A Pending JP2016526920A (ja) | 2013-08-05 | 2014-08-05 | 最適化a−バルジを有する組換えベクター |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3030659A4 (enrdf_load_stackoverflow) |
JP (1) | JP2016526920A (enrdf_load_stackoverflow) |
CN (1) | CN105579581A (enrdf_load_stackoverflow) |
AU (1) | AU2014306093A1 (enrdf_load_stackoverflow) |
CA (1) | CA2920049A1 (enrdf_load_stackoverflow) |
WO (1) | WO2015021077A1 (enrdf_load_stackoverflow) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022551239A (ja) * | 2019-09-30 | 2022-12-08 | シャンハイ インスティチュート オブ マテリア メディカ,チャイニーズ アカデミー オブ サイエンシーズ | 動脈関連疾患を治療するための薬物およびその用途 |
JP2023525720A (ja) * | 2020-05-11 | 2023-06-19 | アビタス バイオ インコーポレイティッド | In vivo形質導入のためのベクター及び方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
AU2020328507A1 (en) | 2019-08-12 | 2022-03-17 | Purinomia Biotech, Inc. | Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells |
TW202128775A (zh) | 2019-10-16 | 2021-08-01 | 英商阿法克塔生命科學有限公司 | PD-L1抑制劑-TGFβ抑制劑雙特異性藥物部分 |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
AU2022212007A1 (en) | 2021-01-29 | 2023-09-07 | Merck Sharp & Dohme Llc | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
EP4412711A1 (en) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
TW202400647A (zh) | 2022-04-29 | 2024-01-01 | 美商普瑞諾生物科技公司 | 用於治療嗜酸性球驅動之疾病及病症的方法及組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050260568A1 (en) * | 2004-04-30 | 2005-11-24 | Min Gao | Hepatitis C virus assays |
JP2012503987A (ja) * | 2008-09-26 | 2012-02-16 | トカジェン インコーポレーテッド | 組換えベクター |
JP2013523754A (ja) * | 2010-03-29 | 2013-06-17 | トカジェン インコーポレーテッド | 組み換えベクターを用いたがんの治療 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
US20110020814A1 (en) * | 2009-06-05 | 2011-01-27 | Ipierian, Inc. | Methods and compositions for selection of stem cells |
SG176890A1 (en) * | 2009-06-17 | 2012-01-30 | Tocagen Inc | Producer cells for replication competent retroviral vectors |
-
2014
- 2014-08-05 CN CN201480053358.9A patent/CN105579581A/zh active Pending
- 2014-08-05 JP JP2016533383A patent/JP2016526920A/ja active Pending
- 2014-08-05 CA CA2920049A patent/CA2920049A1/en not_active Abandoned
- 2014-08-05 WO PCT/US2014/049831 patent/WO2015021077A1/en active Application Filing
- 2014-08-05 AU AU2014306093A patent/AU2014306093A1/en not_active Abandoned
- 2014-08-05 EP EP14835030.9A patent/EP3030659A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050260568A1 (en) * | 2004-04-30 | 2005-11-24 | Min Gao | Hepatitis C virus assays |
JP2012503987A (ja) * | 2008-09-26 | 2012-02-16 | トカジェン インコーポレーテッド | 組換えベクター |
JP2012503986A (ja) * | 2008-09-26 | 2012-02-16 | トカジェン インコーポレーテッド | 遺伝子治療ベクターおよびシトシンデアミナーゼ |
JP2013523754A (ja) * | 2010-03-29 | 2013-06-17 | トカジェン インコーポレーテッド | 組み換えベクターを用いたがんの治療 |
Non-Patent Citations (3)
Title |
---|
DUKE GM ET AL., J VIROL., vol. 66(3)(1992), JPN6018027135, pages 1602 - 1609, ISSN: 0003987920 * |
KAMINSKI A. ET AL., RNA, vol. 4(6)(1998), JPN6018027134, pages 626 - 638, ISSN: 0003987919 * |
ORLINGER K. ET AL., J. VIROL., vol. 81(22)(2007), JPN6018027136, pages 12619 - 12629, ISSN: 0003987918 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022551239A (ja) * | 2019-09-30 | 2022-12-08 | シャンハイ インスティチュート オブ マテリア メディカ,チャイニーズ アカデミー オブ サイエンシーズ | 動脈関連疾患を治療するための薬物およびその用途 |
JP7500715B2 (ja) | 2019-09-30 | 2024-06-17 | シャンハイ インスティチュート オブ マテリア メディカ,チャイニーズ アカデミー オブ サイエンシーズ | 動脈関連疾患を治療するための薬物およびその用途 |
JP2023525720A (ja) * | 2020-05-11 | 2023-06-19 | アビタス バイオ インコーポレイティッド | In vivo形質導入のためのベクター及び方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2015021077A1 (en) | 2015-02-12 |
EP3030659A1 (en) | 2016-06-15 |
CA2920049A1 (en) | 2015-02-12 |
EP3030659A4 (en) | 2017-01-11 |
AU2014306093A2 (en) | 2016-04-21 |
AU2014306093A1 (en) | 2016-03-17 |
CN105579581A (zh) | 2016-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11279949B2 (en) | Recombinant vectors comprising 2A peptide | |
US10407666B2 (en) | Recombinant vectors | |
JP6523224B2 (ja) | 組換えベクター | |
JP6419706B2 (ja) | ミニプロモーターカセットを含むレトロウイルスベクター | |
JP2016526920A (ja) | 最適化a−バルジを有する組換えベクター | |
US20160222412A1 (en) | Recombinant vector with stabilizing a-loop |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170802 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170802 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180717 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190305 |